Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and ASTX727 in AML
NCT04746235Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2021
- Primary completion
- Oct 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, inqovi in acute myeloid leukemia (AML), sponsored by University of Texas MD Anderson Cancer Center. Started Feb 2021; status: active, not recruiting.
02
Drugs
venetoclaxinqovi
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04746235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746235.